Please assess the completion status of the following clinical trial:

Trial Title: Anti-reflux Control to Decrease Post Tonsillectomy Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 7-17 years old~* Weight \>20 kg~* Scheduled to undergo a tonsillectomy (with or without adenoidectomy) in greater than four weeks.~* Health conditions (any of the following): Hypertrophic tonsils and adenoids, sleep disordered breathing, obstructive sleep apnea, chronic or recurrent tonsillitis, halitosis, dysphagia~* Must be able to swallow pills or tolerate taking the medication sprinkled on applesauce or other soft food.~Exclusion Criteria:~* Age \<7~* Weight \<20kg~* Patients declared by the parent not able to communicate pain level.~* Patients whose tonsillectomy is scheduled \<4 weeks from the preoperative assessment (The patient would not have time to complete the preoperative treatment) (An exception to this exclusion criteria will be for the control group)~* Patients with a mental illness. This will be determined by the patient's physician or the physician overseeing the care of the patient.~* Unable to swallow pills or tolerate sprinkling the medication on soft food.~* Pregnant patients~* Any patients already taking Proton Pump Inhibitor

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Omeprazole (Type: ACTIVE_COMPARATOR): Yes. Omeprazole (generic) will be used. Children \>20 kg will be given 20 mg PO daily for 4 weeks prior to tonsillectomy. This is the normal standard pediatric dosing for reflux.~Omeprazole is authorized to treat reflux in children. The study focuses on laryngopharyngeal reflux that possibly contributes to post tonsillectomy pain.
- Sugar pill (Type: PLACEBO_COMPARATOR): The placebo does not look like the omeprazole, however this will not be an issue because none of the subjects will have knowledge of how the medications look.

Based on this trial design, predict the completion outcome and termination type (if applicable).